Clinical Trial Update: A Study to Investigate LYL797 in Adults With Solid Tumors [Phase 1]

View source ↗

Summary

Lyell Immunopharma's Phase 1 study of LYL797 in adults with solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Endometrial Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• LYL797

Snippet

Sponsor: Lyell Immunopharma, Inc. | Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 | Status: TERMINATED